Trial Profile
A Single Centre, Single Arm, Exploratory, Open Label Study to Determine the Early Bone Formation and Bone Resorption Biomarker Response Profile of a Potent Bone Anabolic Treatment (PTH-1-34) with Daily Subcutaneous Administration, in Osteoporotic and Osteopenic Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2015
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Biomarker; Pharmacodynamics
- Sponsors Novartis
- 17 Jun 2015 New trial record